Hyderabad Telangana, India

Dandala Ramesh

This inventor holds 1 USPTO granted patent. Top assignee: Mylan Laboratories Limited. Active years: 2015.


Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Dandala Ramesh: Innovator in Pharmaceutical Chemistry

Introduction

Dandala Ramesh is a notable inventor based in Hyderabad, Telangana, India. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel processes for drug synthesis. His work has implications for the treatment of various medical conditions, showcasing the importance of innovation in healthcare.

Latest Patents

Dandala Ramesh holds a patent for the synthesis of Aliskiren, a renin inhibitor. The patent details a novel process for the preparation of Aliskiren or its derivatives, along with its pharmaceutically acceptable salts. This invention also includes novel intermediates used in the preparation of Aliskiren, highlighting Ramesh's expertise in pharmaceutical synthesis.

Career Highlights

Ramesh is currently associated with Mylan Laboratories Limited, a global leader in generic and specialty pharmaceuticals. His role at Mylan allows him to apply his innovative ideas in a practical setting, contributing to the development of effective medications. His work is crucial in advancing the pharmaceutical industry and improving patient outcomes.

Collaborations

Some of his notable coworkers include Rama Shankar and Vadali Lakshmana Rao. Their collaboration fosters a creative environment that encourages the exchange of ideas and enhances the innovation process within the company.

Conclusion

Dandala Ramesh exemplifies the spirit of innovation in the pharmaceutical industry through his patent for Aliskiren synthesis. His contributions not only advance scientific knowledge but also have a direct impact on healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…